Compare Costco Wholesale Corporation (COST) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Citius Pharmaceuticals Inc — how do they compare? Costco Wholesale Corporation trades at $916.71 (market cap $408.78B), while Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M). The key difference: Costco Wholesale Corporation is far larger — about 27922.1× Citius Pharmaceuticals Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| COST | CTXR | |
|---|---|---|
Market Cap | $408.78B | $14.64M |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $1.82 |
52-Week Low | $849.63 | $0.53 |
Enterprise Value | $396.92B | $10.86M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $916.54, down 1.07% with a bearish technical signal. The company shows strong fundamentals with revenue growth from $275.24B in 2025 to projected $293.6B in 2026 and consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,120 price target, though valuation metrics appear elevated with a P/E of 46.37. Recent March sales surged 11.3% year-over-year, demonstrating resilient consumer demand despite market volatility.
The outlook remains positive given Costco's membership fee growth and expansion strategy, but risks include premium valuation compression and competitive pressures. With strong institutional accumulation and solid cash flow generation, COST offers long-term growth potential for investors comfortable with current multiples. The stock's current pullback near support at $917 may present an entry opportunity for patient investors.
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
